Related Experiment Video
Updated: Aug 14, 2026
12:43
A Protocol for Comprehensive Assessment of Bulbar Dysfunction in Amyotrophic Lateral Sclerosis (ALS)
Published on: February 21, 2011
Treatment efficacy: dysarthria
1Department of Rehabilitation Medicine, University of Washington, Seattle, USA. yorkston@u.washington.edu
Journal of Speech and Hearing Research
|October 1, 1996
Summary
Speech-language pathologists effectively treat dysarthria, a motor speech disorder common in Parkinson's disease, stroke, TBI, ALS, and cerebral palsy. Evidence supports their services for improving communication and aiding informed decisions.
Area of Science:
- Neurology
- Speech-Language Pathology
Background:
- Dysarthria encompasses diverse chronic motor speech disorders.
- It frequently presents as a debilitating symptom in Parkinson's disease, stroke, traumatic brain injury (TBI), amyotrophic lateral sclerosis (ALS), and cerebral palsy.
Observation:
- Speech-language pathologists (SLPs) play crucial roles in diagnosing, treating, and managing dysarthria.
- SLPs provide education for informed decision-making regarding communication alternatives.
Findings:
- Scientific and clinical evidence confirms that individuals with dysarthria benefit significantly from SLP services.
- Various speech treatments, including group and single-subject studies, demonstrate effectiveness.
- Augmentative and alternative communication (AAC) systems show promise for individuals with cerebral palsy.
Implications:
- SLP interventions are vital for managing motor speech disorders like dysarthria.
- Evidence-based practices enhance patient outcomes and communication abilities.
- Further research into AAC systems can improve quality of life for those with specific neurological conditions.
Related Concept Videos
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...